How many sites are enough? a novel, site-based power analysis method for real-world registry studies of anti-amyloid monoclonal antibodies. // The Journal of Aging Research & Lifestyle. – URL: https://www.sciencedirect.com/science/article/pii/S2534773X25000205?dgcid=rss_sd_all
How many sites are enough? a novel, site-based power analysis method for real-world registry studies of anti-amyloid monoclonal antibodies. The Journal of Aging Research & Lifestyle. https://www.sciencedirect.com/science/article/pii/S2534773X25000205?dgcid=rss_sd_all
“How many sites are enough? a novel, site-based power analysis method for real-world registry studies of anti-amyloid monoclonal antibodies.” The Journal of Aging Research & Lifestyle.
@article{article108761,
title = {How many sites are enough? a novel, site-based power analysis method for real-world registry studies of anti-amyloid monoclonal antibodies},
journal = {The Journal of Aging Research \& Lifestyle},
url = {https://www.sciencedirect.com/science/article/pii/S2534773X25000205?dgcid=rss_sd_all}
}
ABSTRACT Introduction/Aims Pompe disease is a genetic myopathy caused by acid alpha‐glucosidase enzyme deficiency. Treatment response is mainly evaluated using motor scores, for instance the 6‐min walk test (6MWT) or the Motor Function...
ABSTRACT Introduction/Aims Inflammatory neuropathies (IN), such as Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), are characterized by peripheral nerve injury driven by immune...